Telomir Pharmaceuticals (TELO) Common Equity (2022 - 2026)
Telomir Pharmaceuticals (TELO) posted Common Equity of $5.9 million for Q4 2025, down 15.27% sequentially from $7.0 million in Q3 2025, and up 885.56% YoY from $600000.0 in Q4 2024.
Telomir Pharmaceuticals (TELO) Common Equity (2022 - 2026) Analysis & Trends
Telomir Pharmaceuticals has reported Common Equity for 4 years, with the latest figure at $5.9 million in Q4 2025.
- Quarterly Common Equity rose 885.56% year-over-year to $5.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $5.9 million (up 885.56% YoY) and the FY2025 annual result came in at $5.9 million, up 885.56% from the prior year.
- Common Equity fell to $5.9 million in Q4 2025 per TELO's latest filing, from $7.0 million in the prior quarter.
- Over five years, Common Equity peaked at $7.0 million in Q3 2025 and troughed at -$937278.0 in Q4 2022.
- A 4-year average of $2.1 million and a median of $1.6 million in 2024 frame the typical range for Common Equity.
- The widest YoY moves for Common Equity: up 1478.77% in 2025, down 105.34% in 2025.
- Over 4 years, Common Equity stood at -$937278.0 in 2022, then soared by 466.83% to $3.4 million in 2023, then slumped by 82.55% to $600000.0 in 2024, then jumped by 885.56% to $5.9 million in 2025.
- According to Business Quant data, Common Equity over the past three periods registered $5.9 million, $7.0 million, and $481223.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.35 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 757.49 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 9.79 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 22.38 Bn |
| 10 | Telomir Pharmaceuticals | 68.14 Mn | 68.14 Mn | - | 5.03 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 5.03 Mn |
| Dec 31, 2025 | 5.91 Mn |
| Sep 30, 2025 | 6.98 Mn |
| Jun 30, 2025 | 481,223.00 |
| Mar 31, 2025 | -161,106.00 |
| Dec 31, 2024 | 600,000.00 |
| Sep 30, 2024 | 442,074.00 |
| Jun 30, 2024 | 1.63 Mn |
| Mar 31, 2024 | 3.02 Mn |
| Dec 31, 2023 | 3.44 Mn |
| Sep 30, 2023 | 2.18 Mn |
| Jun 30, 2023 | 3.89 Mn |
| Mar 31, 2023 | -510,215.00 |
| Dec 31, 2022 | -937,278.00 |